Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - BIOTIME INCa6326855-ex991.htm

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (date of earliest event reported): June 10, 2010




BioTime, Inc.
(Exact name of registrant as specified in its charter)

California

1-12830

94-3127919

(State or other jurisdiction of

incorporation)

(Commission File Number)

 

(IRS Employer

Identification No.)


1301 Harbor Bay Parkway
Alameda, California 94502
(Address of principal executive offices)

(510) 521-3390
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed.  Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions identify forward-looking statements.

Section 5 – Corporate Governance and Management

Item 5.07 - Submission of Matters to a Vote of Security Holders.

Our annual meeting of shareholders was held on June 10, 2010.  At the meeting our shareholders elected eight directors to serve until the next annual meeting and until their successors are duly elected and qualified.  Our shareholders also ratified the Board of Directors’ selection of Rothstein, Kass & Company, P.C. as our independent public auditors to audit our financial statements for the current fiscal year.  There were 33,996,017 outstanding shares of BioTime’s common stock as of April 26, 2010 entitled to vote and 28,891,219 shares, or 84.98%, represented at the meeting, either in person or by proxy. The following tables show the votes cast by our shareholders and any abstentions and broker non-votes with respect to the matters presented to shareholders for a vote at the meeting:

Election of Directors

Nominee

Votes For

Percent of Vote

Votes Withheld

 
Neal C. Bradsher 19,028,087 99.84 29,828
Arnold I. Burns 19,019,240 99.80 38,675
Robert N. Butler 19,021,074 99.81 36,841
Abraham E. Cohen 19,021,895 99.81 36,020
Alfred D. Kingsley 19,029,855 99.85 28,060
Pedro Lichtinger 19,027,745 99.84 30,170
Judith Segall 19,029,251 99.85 28,664
Michael D. West 19,025,355 99.83 32,560

Ratification of Appointment of Independent Auditors

Shares Voted

Percent of Quorum

 
For 28,840,146 99.82
Against 12,744 0.04
Abstain 38,329 0.13
Broker Non-Votes 0 0.00

2

Section 9 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits.

Exhibit Number

Description

99.1 Press release dated June 14, 2010


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

 

 
Date:

June 14, 2010

By:

  /s/ Steven A. Seinberg

Chief Financial Officer

3

Exhibit Number

Description

99.1 Press release dated June 14, 2010

4